CureVac N.V.
CVAC · NASDAQ
Bulios Fair Price
$4.96
7.0% upside
Current Price
$4.64
According to Bulios Fair Price, CVAC is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
CureVac N.V. (CVAC) is a biotechnology company focused on developing innovative drugs and therapies based on messenger RNA (mRNA) technology. The company is dedicated to researching and developing medicines and vaccines targeting various diseases, including infectious diseases, cancer, and other health conditions. CureVac plays a pivotal role in the field of mRNA technology development and its potential in disease treatment and prevention. Their mRNA vaccine against infectious diseases gained significant attention during the COVID-19 pandemic. Shares of CureVac N.V. (CVAC) can be an interesting choice for investors tracking the biotechnology sector and innovations in the field of drugs and vaccines.
Sector
Healthcare
Industry
Biotechnology
CEO
Alexander Zehnder
Employees
825
Headquarters
Tübingen